Dublin, April 02, 2026 (GLOBE NEWSWIRE) — The “Next-Generation Oncology Devices and Solutions Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The next-generation oncology devices and solutions market is set to experience substantial growth, expanding from $16.41 billion in 2025 to $19.46 billion in 2026, with a CAGR of 18.6%. Factors driving this growth include the rising global cancer incidence, enhanced molecular diagnostics, advanced oncology tools, and increased adoption of targeted therapies.
By 2030, the market is projected to reach $38.19 billion, with a CAGR of 18.4%, fueled by demand for personalized cancer treatments, investments in genomic diagnostics, early screening programs, AI integration, and biomarker management advancements.
The cancer prevalence surge, primarily due to aging populations, underscores the need for next-generation oncology solutions, enabling earlier detection and more accurate diagnoses. For instance, in 2024, the American Cancer Society predicted over 611,000 cancer-related deaths annually in the U.S., highlighting the urgent demand for advanced oncology devices.
Innovation remains at the forefront, with companies like Integrated DNA Technologies (IDT) launching the xGen Hybridization and Wash v3 Kit in April 2025 to expedite cancer research. This kit streamlines next-generation sequencing (NGS) workflows, reducing hybridization time and improving automation readiness. Similarly, Hologic’s 2024 acquisition of Endomag enhances its breast cancer surgery portfolio, focusing on precise cancer care.
The market is dominated by major players, including Johnson & Johnson Services Inc., Siemens AG, Merck & Co. Inc., and others, with North America leading the market regionally in 2025. Coverage extends across Asia-Pacific, Europe, South America, and more, with specific insights into countries such as China, India, Japan, and Germany.
Reasons to Purchase:
- Obtain a global perspective with an extensive report covering 16 geographies.
- Analyze the influence of geopolitical factors, trade policies, inflation, interest rates, and regulatory landscapes.
- Formulate regional and country-specific strategies with localized data insights.
- Pinpoint investment opportunities in growth segments.
- Leverage forecast data, market drivers, and trends to gain competitive edge.
- Gain insight into customer behavior through end-user analysis.
- Benchmark against competitors with metrics of market share, innovation, and brand authority.
- Evaluate market potential with total addressable market (TAM) and attractiveness scoring.
- Access a high-quality data and analysis package suitable for presentations.
- Receive the latest data updates in an Excel dashboard for ease of use.
Report Scope:
- Markets Covered: By Cancer Type (e.g., Breast, Cervical, Colorectal, Lung Cancer).
- Technologies: Includes NGS, PCR, DNA Microarrays, among others.
- Applications: Encompasses Screening, Prognostics, Therapy Selection, etc.
- End Use: Hospitals, Labs, Academic Institutions, and more.
Key Companies Mentioned: Johnson & Johnson, Siemens, Merck, Novartis, GE HealthCare, and others.
Countries: Includes major markets like USA, China, Germany, and emerging ones like Taiwan, Indonesia.
Regions: Asia-Pacific, Europe, North America, etc.
Data Features: Provides a five-year historical and ten-year forecast, with data in Word, PDF, and an interactive Excel dashboard.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $19.46 Billion |
| Forecasted Market Value (USD) by 2030 | $38.19 Billion |
| Compound Annual Growth Rate | 18.4% |
| Regions Covered | Global |
The companies featured in this Next-Generation Oncology Devices and Solutions market report include:
- Johnson & Johnson Services Inc.
- Siemens AG
- Merck & Co. Inc.
- Thermo Fisher Scientific Inc.
- Novartis AG
- Koninklijke Philips N.V.
- GE HealthCare Technologies Inc.
- Agilent Technologies Inc.
- Illumina Inc.
- Sysmex Corporation
- QIAGEN N.V.
- Exact Sciences Corporation
- Elekta AB
- Myriad Genetics Inc.
- Takara Bio USA Inc.
- NeoGenomics Inc.
- Guardant Health Inc.
- Accuray Incorporated
- SOPHiA GENETICS SA
- Paige.AI Inc.
- Deep Bio Inc.
- Lucida Medical Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/eapwd3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Next-Generation Oncology Devices and Solutions Market
